⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 11, 2024Hepatology

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study

Sung Won Chung Hye‐Sung Moon Hyun‐Jae Shin Hyein Han Sehoon Park Heejin Cho Jeayeon Park Moon Haeng Hur Min Kyung Park Sungho Won Yun Bin Lee Eun Ju Cho Su Jong Yu Dong Ki Kim Jung‐Hwan Yoon Jeong‐Hoon Lee Yoon Jun Kim

View at Publisher

Ask AI

Bookmark

Share

Abstract

No medication has been found to reduce liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on liver-related outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chung et al. (2024) studied this question.

synapsesocial.com/papers/68e747eeb6db6435876c13dc https://doi.org/10.1097/hep.0000000000000837

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study2024 · 6 citations
2Mendelian randomization study of sodium–glucose cotransporter 2 inhibitors in cardiac and renal diseases2024 · 3 citations
3Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores2024 · 2 citations
4SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study2024 · 8 citations
5Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes.Human Clinical Trial · 2026

More related papers

Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study2024
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease2024
Metabolic Impact of Sodium-Glucose Cotransporter 2 Inhibitor-Induced Ketogenesis in Type 2 Diabetes Mellitus2026

More from Hepatology

Trends in the etiologies and outcomes of idiosyncratic drug-induced liver injury in the united states: The DILIN prospective registry, 2004 to 2024Fri,
Single-cell landscape of alcohol-related hepatitis reveals serum amyloid a hepatocytes as key drivers of disease pathogenesisFri,